Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. [electronic resource]
Producer: 20180507Description: 799-812 p. digitalISSN:- 1941-837X
- Bone Density Conservation Agents -- administration & dosage
- Bone Diseases -- etiology
- Breast Neoplasms -- complications
- Cost-Benefit Analysis
- Czech Republic
- Denosumab -- administration & dosage
- Diphosphonates -- administration & dosage
- Double-Blind Method
- Female
- Humans
- Imidazoles -- administration & dosage
- Male
- Markov Chains
- Models, Econometric
- Neoplasms -- complications
- Prostatic Neoplasms -- complications
- Quality of Life
- Quality-Adjusted Life Years
- Zoledronic Acid
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.